Seattle Genetics, GSK in Next-Generation Antibody Deal
This article was originally published in The Pink Sheet Daily
Seattle Genetics' third deal in two months signals big pharma's growing interest in antibody conjugate technology or "empowered" antibodies for immunotherapies targeting cancer and other hard-to-treat diseases.
You may also be interested in...
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.